MicroRNAs and exosomes: Cardiac stem cells in heart diseases

Maleki, Behnaz; Alani, Behrang; Zadeh, Seyed Saeed Tamehri; Saadat, Somayeh; Rajabi, Ali; Ayoubzadeh, Seyed Mohammad Jalal; Farrokhian, Alireza; Ghanbarian, Hossein; Noureddini, Mahdi; Nejati, Majid

doi:10.1016/j.prp.2021.153701

Cited by 13 publications

(8 citation statements)

References 216 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Treating cardiovascular diseases with cardiac stem cells is a valid treatment. Cardiac stem cells can reproduce the myocardial cells [ 66 , 161 , 162 ]. Studies have shown that cardiac stem cell proliferation and differentiation are regulated by microRNAs [ 161 , 162 ].…”

Section: Therapeutic Approach Based On Micrornas and Their Ability To...mentioning

confidence: 99%

Cardiac microRNAs: diagnostic and therapeutic potential

Kabłak-Ziembicka,

Badacz,

Okarski

et al. 2023

Arch Med Sci

View full text Add to dashboard Cite

MicroRNAs are small non-coding post-translational biomolecules which, when expressed, modify their target genes. It is estimated that microRNAs regulate production of approximately 60% of all human proteins and enzymes that are responsible for major physiological processes. In cardiovascular disease pathophysiology, there are several cells that produce microRNAs, including endothelial cells, vascular smooth muscle cells, macrophages, platelets, and cardiomyocytes. There is a constant crosstalk between microRNAs derived from various cell sources. Atherosclerosis initiation and progression are driven by many pro-inflammatory and pro-thrombotic microRNAs. Atherosclerotic plaque rupture is the leading cause of cardiovascular death resulting from acute coronary syndrome (ACS) and leads to cardiac remodeling and fibrosis following ACS. MicroRNAs are powerful modulators of plaque progression and transformation into a vulnerable state, which can eventually lead to plaque rupture. There is a growing body of evidence which demonstrates that following ACS, microRNAs might inhibit fibroblast proliferation and scarring, as well as harmful apoptosis of cardiomyocytes, and stimulate fibroblast reprogramming into induced cardiac progenitor cells. In this review, we focus on the role of cardiomyocyte-derived and cardiac fibroblast-derived microRNAs that are involved in the regulation of genes associated with cardiomyocyte and fibroblast function and in atherosclerosis-related cardiac ischemia. Understanding their mechanisms may lead to the development of microRNA cocktails that can potentially be used in regenerative cardiology.

show abstract

Section: Therapeutic Approach Based On Micrornas and Their Ability To...mentioning

confidence: 99%

Cardiac microRNAs: diagnostic and therapeutic potential

Kabłak-Ziembicka,

Badacz,

Okarski

et al. 2023

Arch Med Sci

View full text Add to dashboard Cite

show abstract

“…Noncoding RNAs, such as miRNAs, lncRNAs, and circular RNAs, play crucial roles in regulating gene expression and cellular processes. In recent years, noncoding RNAs have gained greater interest due to studies implicating them in the regulation of MSC proliferation and differentiation [ 42 ]. miRNAs are a class of small noncoding RNAs that play a crucial role in the post-transcriptional regulation of gene expression.…”

Section: Msc-derived Exosomes and Noncoding Rnasmentioning

confidence: 99%

Mesenchymal Stem Cell-Derived Long Noncoding RNAs in Cardiac Injury and Repair

Tran,

Cruz,

Chan

et al. 2023

Cells

View full text Add to dashboard Cite

Cardiac injury, such as myocardial infarction and heart failure, remains a significant global health burden. The limited regenerative capacity of the adult heart poses a challenge for restoring its function after injury. Mesenchymal stem cells (MSCs) have emerged as promising candidates for cardiac regeneration due to their ability to differentiate into various cell types and secrete bioactive molecules. In recent years, attention has been given to noncoding RNAs derived from MSCs, particularly long noncoding RNAs (lncRNAs), and their potential role in cardiac injury and repair. LncRNAs are RNA molecules that do not encode proteins but play critical roles in gene regulation and cellular responses including cardiac repair and regeneration. This review focused on MSC-derived lncRNAs and their implications in cardiac regeneration, including their effects on cardiac function, myocardial remodeling, cardiomyocyte injury, and angiogenesis. Understanding the molecular mechanisms of MSC-derived lncRNAs in cardiac injury and repair may contribute to the development of novel therapeutic strategies for treating cardiovascular diseases. However, further research is needed to fully elucidate the potential of MSC-derived lncRNAs and address the challenges in this field.

show abstract

“…Cardiovascular disease (CVDs) accounts for the majority of deaths worldwide ( 1 , 2 ), and is more predominant in older generation ( 3 ). According to WHO report, CVDs accounted for 17.9 million deaths in 2019, representing 32% of all global deaths ( 3 – 8 ). Although the mortality rate is now being reduced, the prevalence of CVDs still remains too high ( 9 ).…”

Section: Introductionmentioning

confidence: 99%

Evidence for the Benefits of Melatonin in Cardiovascular Disease

Tobeiha

Jafari

Fadaei

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

The pineal gland is a neuroendocrine gland which produces melatonin, a neuroendocrine hormone with critical physiological roles in the circadian rhythm and sleep-wake cycle. Melatonin has been shown to possess anti-oxidant activity and neuroprotective properties. Numerous studies have shown that melatonin has significant functions in cardiovascular disease, and may have anti-aging properties. The ability of melatonin to decrease primary hypertension needs to be more extensively evaluated. Melatonin has shown significant benefits in reducing cardiac pathology, and preventing the death of cardiac muscle in response to ischemia-reperfusion in rodent species. Moreover, melatonin may also prevent the hypertrophy of the heart muscle under some circumstances, which in turn would lessen the development of heart failure. Several currently used conventional drugs show cardiotoxicity as an adverse effect. Recent rodent studies have shown that melatonin acts as an anti-oxidant and is effective in suppressing heart damage mediated by pharmacologic drugs. Therefore, melatonin has been shown to have cardioprotective activity in multiple animal and human studies. Herein, we summarize the most established benefits of melatonin in the cardiovascular system with a focus on the molecular mechanisms of action.

show abstract

MicroRNAs and exosomes: Cardiac stem cells in heart diseases

Cited by 13 publications

References 216 publications

Cardiac microRNAs: diagnostic and therapeutic potential

Cardiac microRNAs: diagnostic and therapeutic potential

Mesenchymal Stem Cell-Derived Long Noncoding RNAs in Cardiac Injury and Repair

Evidence for the Benefits of Melatonin in Cardiovascular Disease

Contact Info

Product

Resources

About